0001171000-15-000039.txt : 20150702
0001171000-15-000039.hdr.sgml : 20150702
20150702123922
ACCESSION NUMBER: 0001171000-15-000039
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150630
FILED AS OF DATE: 20150702
DATE AS OF CHANGE: 20150702
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nexvet Biopharma plc
CENTRAL INDEX KEY: 0001618561
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: NATL INST FOR BIOPROCESSING RESEARCH
STREET 2: FOSTERS AVENUE, MOUNT MERRION
CITY: BLACKROCK CO. DUBLIN
STATE: L2
ZIP: 00000
BUSINESS PHONE: 353 1 215 8100
MAIL ADDRESS:
STREET 1: NATL INST FOR BIOPROCESSING RESEARCH
STREET 2: FOSTERS AVENUE, MOUNT MERRION
CITY: BLACKROCK CO. DUBLIN
STATE: L2
ZIP: 00000
FORMER COMPANY:
FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd
DATE OF NAME CHANGE: 20140903
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hanna Ashraf
CENTRAL INDEX KEY: 0001632436
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36828
FILM NUMBER: 15968172
MAIL ADDRESS:
STREET 1: C/O NEXVET BIOPHARMA PLC
STREET 2: NATL INST, FOSTERS AVENUE, MOUNT MERRION
CITY: BLACKROCK
STATE: L2
ZIP: 00000
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2015-06-30
1
0001618561
Nexvet Biopharma plc
NVET
0001632436
Hanna Ashraf
C/O NEXVET BIOPHARMA PLC
NIBRT; FOSTERS AVENUE, MOUNT MERRION
BLACKROCK, CO. DUBLIN
L2
IRELAND
1
0
0
0
Ordinary Shares
2015-06-30
4
M
0
900
.125
A
4320
D
Ordinary Shares
2015-06-30
4
M
0
500
.125
A
4820
D
Restricted Share Units
.125
2015-06-30
4
M
0
900
0
D
2015-06-30
2019-07-01
Ordinary Shares
900
0
D
Restricted Share Units
.125
2015-06-30
4
M
0
500
0
D
2015-06-30
2019-07-01
Ordinary Shares
500
4000
D
500 of the Restricted Share Units vested and became convertible on 6/30/15, and shall vest and become convertible with respect to an additional 500 shares on each of 9/30/15, 12/31/15, 3/31/16, 6/30/16, 9/30/16, 12/31/16, 3/31/17 and 6/30/17, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.
/s/ Ashraf Hanna by Geraldine T. Farrell, Attorney-in-Fact
2015-07-02